Andrea Knight

Dr. Andrea Knight is a Senior Lecturer in the School of Life Sciences within the Faculty of Science and Engineering at Anglia Ruskin University, Cambridge. She joined the university in July 2024 and leads an active research group focused on human gamma-delta T cells in malignant disorders.

Her educational background includes:

• PhD from University College London
• MSc in Immunology
• BSc in Immunology

Dr. Knight's research spans innate immunity, tumour immunology, and the tumour microenvironment in blood cancers (including Multiple Myeloma, CML, and CLL) and glioblastoma. Her work extends to endometriosis, cytomegalovirus, immune reconstitution post-transplantation, and Yamanaka transcription factor mechanisms. She investigates how tumour-infiltrating immune cells affect patient prognosis and strategies to overcome immunosuppression in the tumour microenvironment.

Her recent publications (2021-2024) reveal dual research thrusts: molecular mechanisms of transcription activation domains (particularly 9aaTAD in Myc, NFkB, and Yamanaka factors) and gamma-delta T cell immunology in cancer. This bridges fundamental molecular biology with clinical oncology, offering insights for novel immunotherapies targeting tumour microenvironments.

Dr. Knight is a member of the UK CLL Forum and UK Myeloma Forum, but no specific scientific awards were listed in the provided information.

She actively supervises MSc/PhD students and has secured substantial research funding as principal investigator from Blood Cancer UK, Royal Free Charity, Marie Sklodowska-Curie Actions, Wingate Scholarship, Czech Health Research Council (twice), Masaryk University Brno (twice), and University Hospital Brno (four times).

Her research group specializes in human gamma-delta T cell dynamics within malignant disorders, focusing on immunosurveillance mechanisms and tumour microenvironment interactions across blood cancers and solid tumours.